Evidence map›Paper›PMID 29483185›Full record

Trial reportDiabetes care2018

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.

Liana K Billings, Ankur Doshi, Didier Gouet, Alejandra Oviedo, Helena W Rodbard, Nikolaos Tentolouris, Randi Grøn, Natalie Halladin, Esteban Jodar

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02420262. Cited by 101 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 6 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02420262 phase3completed

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Ran2015Enrolled506Registered outcomes5Posted comparisons3ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsInsulin Aspart, insulin degludec/liraglutide, Insulin glargine
Open the trial in the graph
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 6 syntheses or guidelines pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  6. Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 6 countries.

Liana K BillingsNorthShore University HealthSystem, Evanston, IL lbillings@northshore.org.ORCID 0000-0001-7991-3010
Ankur DoshiPrimeCare Medical Group, Houston, TX.
Didier GouetLa Rochelle Hospital, La Rochelle, France.
Alejandra OviedoSantojanni Hospital and Cenudiab, Ciudad Autonoma de Buenos Aires, Argentina.
Helena W RodbardEndocrine and Metabolic Consultants, Rockville, MD.ORCID 0000-0002-6187-8445
Nikolaos TentolourisMedical School, National and Kapodistrian University of Athens, Athens, Greece.
Randi GrønNovo Nordisk A/S, Søborg, Denmark.
Natalie HalladinNovo Nordisk A/S, Søborg, Denmark.
Esteban JodarH. U. QuirónSalud Madrid y Ruber Juan Bravo, Universidad Europea de Madrid, Madrid, Spain.
Novo Nordisk (Denmark) · DKCentre Hospitalier de La Rochelle · FRHospital Donación Francisco Santojanni · ARNational and Kapodistrian University of Athens · GRNorthShore University HealthSystem · USUniversidad Europea de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn patients with uncontrolled type 2 diabetes on basal insulin, prandial insulin may be initiated. We assessed the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus basal-bolus insulin. RESEARCH DESIGN AND

methodsA phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day.

resultsGlycated hemoglobin (HbA

conclusionsIn patients with uncontrolled type 2 diabetes on IGlar U100 and metformin, IDegLira treatment elicited HbA

Indexed as

AdultAgedBlood GlucoseDiabetes Mellitus, Type 2Drug CombinationsDrug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemic AgentsInsulinInsulin AspartInsulin GlargineInsulin, Long-ActingLiraglutideMaleBlood GlucoseDrug CombinationsGlycated HemoglobinHypoglycemic AgentsIDegLiraInsulinInsulin Aspartinsulin degludec, insulin aspart drug combinationInsulin GlargineInsulin, Long-ActingLiraglutideMetformin

Identifiers

PMID29483185
OpenAlexW2792254305

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.